Objectives: To identify the potential inhibitors isolated from Annona muricata leaves against the epidermal growth factor of tyrosine kinase receptor, a crucial factor involved in the development of breast cancer. Methods: In this study, the ethanolic extract of Annona muricata leaves was studied by GC-MS analysis. The functional compounds derived from the GC-MS spectrum were docked with a target molecule, the Epidermal Growth Factor of Tyrosine Kinase Receptor [PDB Id: 1M17], for breast cancer using Auto dock vina. The Bioactivities of compounds against the key role enzymes like GPCR ligand, nuclear, and enzyme inhibitor in Breast Cancer was analyzed using Molinspiration. The pharmacokinetic and pharmacodynamic attributes of the chemical compounds were studied by the Swiss ADME tool. Findings: The outcomes from Molecular docking proved that the bioactive compounds such as 9,19-Cyclolanost-24-en-3-ol, (3.beta.), Octadec - 9 - enoic acid, Cycloeucalenol, and Phytol could act as potentially active inhibitors against the Epidermal Growth Factor of Tyrosine Kinase Receptor in Breast Cancer. Novelty: The inhibitory effect of the bioactive components from the ethanolic extract of Annona muricata leaves against the Epidermal Growth Factor of Tyrosine Kinase Receptor through the in silico approach has not been explored. This research work will be the first to attempt the in silico mode to determine the potential inhibitors of the Epidermal Growth Factor of Tyrosine Kinase Receptor and successfully identified four bioactive compounds that down-regulate the expression of EGFR and control the proliferation of breast cancer cells. Keywords: Drug Development, Breast Cancer, Inhibitor, Pharmacokinetics, Pharmacodynamics, Auto Docking, Bioactive Compounds